Compare CAKE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | MIRM |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 5.7B |
| IPO Year | 1996 | 2019 |
| Metric | CAKE | MIRM |
|---|---|---|
| Price | $59.67 | $102.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $60.31 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.2M | 847.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $3,751,806,000.00 | $19,138,000.00 |
| Revenue This Year | $6.14 | $26.22 |
| Revenue Next Year | $6.65 | $22.04 |
| P/E Ratio | $57.25 | ★ N/A |
| Revenue Growth | ★ 4.75 | N/A |
| 52 Week Low | $43.07 | $42.89 |
| 52 Week High | $69.70 | $114.99 |
| Indicator | CAKE | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 51.75 |
| Support Level | $57.32 | $87.26 |
| Resistance Level | $64.48 | $107.51 |
| Average True Range (ATR) | 2.40 | 6.60 |
| MACD | -0.43 | 0.47 |
| Stochastic Oscillator | 39.86 | 51.68 |
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.